Physician profile
Robert C Goldstein
NPI 1992730279
$9,876.11
in general payments reported to CMS, 2019-2025
37 companies · $1,738 in 2025
The $1,738 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,309 · 2020: $385 · 2021: $2,780 · 2022: $1,094 · 2023: $1,212 · 2024: $1,358 · 2025: $1,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,286 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,286.39 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,204.10 | 2019-2025 | |
| Redhill Biopharma INC. | $1,869.81 | 2021-2022 | |
| Janssen Biotech, INC. | $808.50 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $802.86 | 2019-2024 | Xifaxan, Trulance |
| Braintree Laboratories, INC. | $625.67 | 2019-2025 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $428.28 | 2019-2024 | Linzess |
| Genzyme Corporation | $409.58 | 2022-2025 | |
| Madrigal Pharmaceuticals | $409.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $300.99 | 2019-2025 | |
| Pfizer INC. | $245.76 | 2019-2025 | |
| Ardelyx, INC. | $234.50 | 2023-2025 | Ibsrela |
| Celgene Corporation | $211.33 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $165.98 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $164.82 | 2019-2024 | Entyvio, Eohilia |
| Medtronic USA, INC. | $155.48 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $144.27 | 2019-2022 | |
| Qol Medical, LLC | $99.13 | 2019-2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $86.88 | 2023-2025 | Dupixent |
| Allergan, INC. | $62.90 | 2019-2020 | |
| Evoke Pharma, INC. | $57.27 | 2021-2023 | Gimoti |
| Intercept Pharmaceuticals, INC. | $55.95 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $43.01 | 2021-2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $34.97 | 2024-2025 | Voquezna |
| Digestive Care, INC. | $33.99 | 2024 | Pertzye |
| Abbott Laboratories | $29.04 | 2022 | |
| Sun Pharmaceutical Industries INC. | $25.44 | 2021 | |
| Vivus LLC | $23.86 | 2019 | |
| Daiichi Sankyo INC. | $18.92 | 2022 | |
| Medtronic, INC. | $18.23 | 2021 | |
| Echosens North America, INC. | $16.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.43 | 2023 | Cyltezo |
| Shionogi INC | $15.19 | 2020 | |
| Fresenius Kabi USA, LLC | $15.03 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $11.56 | 2019 | |
| Concordia Pharmaceuticals INC. | $11.09 | 2019 | |
| Romark Laboratories, Lc | $11.05 | 2020 | |
| Intra-Sana Laboratories | $8.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.